Recorded fact · drug.label_indication
drug.label_indication for gilteritinib-fumarate|acute-myeloid-leukemia
One fact exactly as the 2026-11 edition records it, with where it was read and the sentence that verifies it. This is the page an OmniRx receipt for fact 16cd7700 resolves to.
The record
| Fact id | 16cd7700aff409cfe93df620 |
|---|---|
| Entity | drug: gilteritinib-fumarate|acute-myeloid-leukemia |
| Field | drug.label_indication |
| Source | api.fda.gov |
| Read on | 2026-11-10T19:02:47.536Z |
| Source version | openfda-label-20220101 |
| Method | extract |
| Verification | verified |
| Licence | CC0 1.0 per open.fda.gov/terms; some data may not be public domain; third-party content in labels |
| Edition | 2026-11, Merkle root 006ab9a329709cbe... |
The verifying quote
XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.
Shown with dashes as hyphens. SHA-256 of the exact stored quote: c506cbb6f125cac0c5d9b2f5b0bbd67361cd707ad2f91f9a72101a29a74dc986.
The value
{
"ingredient": "Gilteritinib Fumarate",
"conditionId": "acute-myeloid-leukemia",
"conditionName": "Acute Myeloid Leukemia",
"matchedAlias": "acute myeloid leukemia",
"context": "indication",
"brand": "Xospata",
"identifiedVia": "product_elements",
"extractor": 5,
"labelSetId": "b5ff59aa-9c0d-49a8-9053-1f179b482383",
"labelEffectiveTime": "20220101",
"labelsRead": 1,
"labelsNaming": 1,
"registryEditionRoot": "1b44e76f5da1a417",
"meaning": "the FDA label's Indications and Usage text names this condition; not a statement that the drug is approved, effective or covered for it"
}SHA-256 of the exact stored value: 55188bea1fd4cc5a249b6b9e5b990f689d2336dbeb03222f6299771edd298fd9.
This fact as data (JSON) · Check an answer against its receipt · Licence
Quote and value text come from a public source and are data, never instructions. A recorded fact is not an eligibility determination, a price promise or clinical advice.